Global GlaucomaEye Drops Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alphaagonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others(rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication(Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel(Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition(Preservative Free, BAK-Based and Non BAK-Based Preservatives ), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),is estimated to be valued at US$ 1,360.1 million in 2020 and is expected toexhibit a CAGR of 7.0% during the forecast period (2020-2027), as highlightedin a new report published by Coherent Market Insights.
Key players in the market have anumber of drugs undergoing clinical trials for treatment of glaucoma and areexpected to receive approval in the near future. The robust pipeline ofglaucoma medications is expected to drive growth of global glaucoma eye dropsmarket in the near future. For instance, in January 2019, Santen PharmaceuticalCo., Ltd. started a clinical trial on drug candidate DE-111A (that is apreservative-free, clear, colorless sterile aqueous ophthalmic solutioncontaining 0.015mg of tafluprost and 5.0mg of timolol in 1mL) for the treatmentof open-angle glaucoma, and ocular hypertension. The clinical trial included324 patients. This clinical trial is in phase 3 and is expected to complete bythe end of June 2020.
Similarly, Zhaoke (Guangzhou)Ophthalmology Pharmaceutical Ltd., China in November 2015, initiated a clinicaltrial with Levobetaxolol eye drops for treatment of primary open-angle glaucomaand ocular hypertension.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3984
This study is to evaluate thesafety and efficacy of Levobetaxolol in Chinese patients with glaucoma. Thisstudy included 366 Chinese patients with glaucoma. The clinical trial is inphase 3 and is expected to be completed by December 2021.
There have been severaldevelopments in glaucoma medications in the recent past. Therefore, robustpipeline for treatment of glaucoma is expected to boost the glaucoma eye dropsmarket growth in the near future.
Browse 25 Market Data Tables and28 Figures spread through 144 Pages and in-depth TOC on Glaucoma Eye DropsMarket, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha agonists,Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others(rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication(Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel(Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition(Preservative Free, BAK-Based and Non BAK-Based Preservatives ), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-Forecast to 2027"
Key Takeaways of the Glaucoma EyeDrops Market:
The global glaucoma eye dropsmarket is expected to exhibit a CAGR of 7.0% during the forecast period(2020-2027) owing to the robust product pipeline for treatment of glaucoma.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/glaucoma-eye-drops-market-3984
Among drug type, the consumablessegment is expected to hold a major revenue share in 2027 owing to productapprovals by regulatory bodies. For instance, in November 2017, Bausch Health,a global eye health company, and Nicox S.A., an international ophthalmiccompany, announced that the U.S. Food and Drug Administration (FDA) approvedthe New Drug Application (NDA) for VYZULTA (latanoprostene bunod ophthalmicsolution, 0.024%) for glaucoma.
Major players operating in theglobal glaucoma eye drops market are Merck & Co., Inc., Allergan Plc.Novartis AG. Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & LombInc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., AeriePharmaceutical, and Mylan N.V.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3984
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
